Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4239858 | 0.92 | RORC (0.34) | SPRHCRTR1HCRTR2MEN1KMT2A | |
| SCHEMBL4241487 | 0.89 | KMT2A (0.35) | SPRPDE4DMEN1KMT2A | |
| SCHEMBL4235967 | 0.86 | RORC (0.38) | SPRMEN1KMT2A | |
| SCHEMBL4242140 | 0.85 | DHODH (0.35) | — | |
| SCHEMBL4244845 | 0.85 | PARP1 (0.36) | — | |
| SCHEMBL4240859 | 0.83 | CRBN (0.32) | — | |
| SCHEMBL4243833 | 0.83 | KDM4E (0.31) | — | |
| Hydrochloric Acid SCHEMBL4242508 | 0.82 | CRBN (0.32) | — | |
| SCHEMBL4235330 | 0.82 | HTR4 (0.34) | — | |
| SCHEMBL4239785 | 0.81 | ALDH1A1 (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093473-A1 | Spiro-benzimidazoles as inhibitors of gastric acid secretion | NYCOMED GMBH (DE) | 2009-04-09 | — | — | US | claimed |
| US-20090093473-A1 | Spiro-benzimidazoles as inhibitors of gastric acid secretion | NYCOMED GMBH (DE) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093473-A1 | Spiro-benzimidazoles as inhibitors of gastric acid secretion | GIPR, PGC, SLC10A2 | SPR 2461/4885GRIN2B 2219/4885HCRTR1 1218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.